Annual report pursuant to Section 13 and 15(d)

Note 9 - Investment in Macrophage Therapeutics, Inc. (Details Textual)

v3.21.1
Note 9 - Investment in Macrophage Therapeutics, Inc. (Details Textual) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended
Mar. 11, 2015
Nov. 30, 2018
Jul. 31, 2016
Mar. 31, 2015
May 31, 2016
Dec. 31, 2017
Dec. 31, 2015
Dec. 31, 2020
Mar. 31, 2020
Dec. 31, 2019
Aug. 31, 2018
Preferred Stock, Shares Authorized (in shares)               5,000,000   5,000,000  
Preferred Stock, Par or Stated Value Per Share (in dollars per share)               $ 0.001   $ 0.001  
Preferred Stock, Shares Issued, Total (in shares)               0   0  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)               992,000      
Derivative Liability, Total $ 63,000                 $ 0  
Preferred Convertible Stock, Right to Exchange for Common Shares, Minimum Required Proceeds from Initial Public Offering             $ 50,000,000        
Weighted Average Price Common Stock Percentage             80.00%        
Future Common Stock Conversion Share Price (in dollars per share)             $ 60        
Reclassification of Funds Invested           $ 200,000          
Former Chief Executive Officer and President [Member]                      
Common Stock Shares Provided by Agreement (in shares)                     1,175,000
Dr. Michael Goldberg [Member]                      
Convertible Preferred Stock, Percent of Shares Reserved       40.00%              
Dr. Michael Goldberg [Member] | MT [Member]                      
Payments to Acquire Businesses and Interest in Affiliates, Total     $ 200,000                
Resignation Agreement, Subidiary Percentage Ownership After Signing                     5.00%
Resignation Agreement, Shares Issued (in shares)   925,000                  
Resignation Agreement, Shares in Escrow (in shares)   250,000                  
Macrophage Therapeutics [Member]                      
Common Stock Shares Authorized Upon Exercise of Warrants (in shares)       1,500              
Convertible Preferred Stock Shares Issued Upon Conversion, Per Unit (in shares)       1              
Common Stock Warrants, Issued Upon Conversion, Per Unit (in shares)       30              
Macrophage Therapeutics [Member] | Common Stock [Member]                      
Common Stock as Percentage of Common Equity       1.00%              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 300               300    
Platinum [Member] | MT [Member]                      
Payments to Acquire Businesses and Interest in Affiliates, Total     $ 300,000   $ 200,000            
MT [Member]                      
Convertible Preferred Stock, PIK Coupon, Percentage     10.00%                
Convertible Preferred Stock, Conversion Price, Market Cap     $ 500,000,000                
Convertible Preferred Stock [Member]                      
Preferred Stock, Shares Authorized (in shares)       50              
Preferred Stock, Par or Stated Value Per Share (in dollars per share)       $ 50,000              
Cumulative Preferred Stock [Member]                      
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants, Total $ 500,000                    
Issuance of Stock and Warrants for Purchase Agreement, Remaining Amount             $ 2,000,000        
Preferred Stock, Fair Value Put Option             113,000        
Future Common Stock Conversion Denominator, Value             $ 50,000        
Cumulative Preferred Stock [Member] | Macrophage Therapeutics [Member]                      
Preferred Stock, Shares Authorized (in shares)       50              
Preferred Stock, Shares Issued, Total (in shares)       10              
Preferred Stock, Redemption Price Per Share (in dollars per share)             $ 58,320